Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
10.47
+0.33 (3.25%)
Jun 18, 2025, 4:00 PM - Market closed
Adaptive Biotechnologies Revenue
Adaptive Biotechnologies had revenue of $52.44M in the quarter ending March 31, 2025, with 25.24% growth. This brings the company's revenue in the last twelve months to $189.53M, up 8.61% year-over-year. In the year 2024, Adaptive Biotechnologies had annual revenue of $178.96M with 5.10% growth.
Revenue (ttm)
$189.53M
Revenue Growth
+8.61%
P/S Ratio
8.17
Revenue / Employee
$306,183
Employees
619
Market Cap
1.59B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ADPT News
- 20 days ago - Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers - GlobeNewsWire
- 21 days ago - Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Adaptive Biotechnologies Corporation (ADPT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Adaptive Biotechnologies Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 - GlobeNewsWire
- 2 months ago - Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma - GlobeNewsWire
- 3 months ago - Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma - GlobeNewsWire
- 4 months ago - Adaptive Biotechnologies Corporation (ADPT) Q4 2024 Earnings Call Transcript - Seeking Alpha